Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.
Identifieur interne : 000706 ( PubMed/Curation ); précédent : 000705; suivant : 000707Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.
Auteurs : Caroline Moreau [France] ; Arnaud Delval ; Vincent Tiffreau ; Luc Defebvre ; Kathy Dujardin ; Alain Duhamel ; Gregory Petyt ; Claude Hossein-Foucher ; David Blum ; Bernard Sablonnière ; Susanna Schraen ; Delphine Allorge ; Alain Destée ; Régis Bordet ; David DevosSource :
- Journal of neurology, neurosurgery, and psychiatry [ 1468-330X ] ; 2013.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Disability Evaluation, Double-Blind Method, Dyskinesia, Drug-Induced (prevention & control), Female, Gait Disorders, Neurologic (drug therapy), Gait Disorders, Neurologic (etiology), Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Memantine (adverse effects), Memantine (therapeutic use), Middle Aged, Parkinson Disease (drug therapy), Pilot Projects, Sample Size.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa, Memantine.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa, Memantine.
- drug therapy : Gait Disorders, Neurologic, Parkinson Disease.
- etiology : Gait Disorders, Neurologic.
- prevention & control : Dyskinesia, Drug-Induced.
- Aged, Aged, 80 and over, Disability Evaluation, Double-Blind Method, Female, Humans, Male, Middle Aged, Pilot Projects, Sample Size.
Abstract
Given that memantine is thought to decrease N-methyl-D-aspartic-acid-related (NMDA) glutamatergic hyperactivity and improve locomotion in rats, we sought to assess the drug's impact on axial symptoms in advanced Parkinson's disease (PD).
DOI: 10.1136/jnnp-2012-303182
PubMed: 23077087
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000738
Links to Exploration step
pubmed:23077087Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.</title><author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Lille Nord de France and Lille University Hospital, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, University of Lille Nord de France and Lille University Hospital, Lille</wicri:regionArea></affiliation></author><author><name sortKey="Delval, Arnaud" sort="Delval, Arnaud" uniqKey="Delval A" first="Arnaud" last="Delval">Arnaud Delval</name></author><author><name sortKey="Tiffreau, Vincent" sort="Tiffreau, Vincent" uniqKey="Tiffreau V" first="Vincent" last="Tiffreau">Vincent Tiffreau</name></author><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name></author><author><name sortKey="Duhamel, Alain" sort="Duhamel, Alain" uniqKey="Duhamel A" first="Alain" last="Duhamel">Alain Duhamel</name></author><author><name sortKey="Petyt, Gregory" sort="Petyt, Gregory" uniqKey="Petyt G" first="Gregory" last="Petyt">Gregory Petyt</name></author><author><name sortKey="Hossein Foucher, Claude" sort="Hossein Foucher, Claude" uniqKey="Hossein Foucher C" first="Claude" last="Hossein-Foucher">Claude Hossein-Foucher</name></author><author><name sortKey="Blum, David" sort="Blum, David" uniqKey="Blum D" first="David" last="Blum">David Blum</name></author><author><name sortKey="Sablonniere, Bernard" sort="Sablonniere, Bernard" uniqKey="Sablonniere B" first="Bernard" last="Sablonnière">Bernard Sablonnière</name></author><author><name sortKey="Schraen, Susanna" sort="Schraen, Susanna" uniqKey="Schraen S" first="Susanna" last="Schraen">Susanna Schraen</name></author><author><name sortKey="Allorge, Delphine" sort="Allorge, Delphine" uniqKey="Allorge D" first="Delphine" last="Allorge">Delphine Allorge</name></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destée">Alain Destée</name></author><author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Régis" last="Bordet">Régis Bordet</name></author><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23077087</idno><idno type="pmid">23077087</idno><idno type="doi">10.1136/jnnp-2012-303182</idno><idno type="wicri:Area/PubMed/Corpus">000738</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000738</idno><idno type="wicri:Area/PubMed/Curation">000706</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000706</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.</title><author><name sortKey="Moreau, Caroline" sort="Moreau, Caroline" uniqKey="Moreau C" first="Caroline" last="Moreau">Caroline Moreau</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Lille Nord de France and Lille University Hospital, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, University of Lille Nord de France and Lille University Hospital, Lille</wicri:regionArea></affiliation></author><author><name sortKey="Delval, Arnaud" sort="Delval, Arnaud" uniqKey="Delval A" first="Arnaud" last="Delval">Arnaud Delval</name></author><author><name sortKey="Tiffreau, Vincent" sort="Tiffreau, Vincent" uniqKey="Tiffreau V" first="Vincent" last="Tiffreau">Vincent Tiffreau</name></author><author><name sortKey="Defebvre, Luc" sort="Defebvre, Luc" uniqKey="Defebvre L" first="Luc" last="Defebvre">Luc Defebvre</name></author><author><name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name></author><author><name sortKey="Duhamel, Alain" sort="Duhamel, Alain" uniqKey="Duhamel A" first="Alain" last="Duhamel">Alain Duhamel</name></author><author><name sortKey="Petyt, Gregory" sort="Petyt, Gregory" uniqKey="Petyt G" first="Gregory" last="Petyt">Gregory Petyt</name></author><author><name sortKey="Hossein Foucher, Claude" sort="Hossein Foucher, Claude" uniqKey="Hossein Foucher C" first="Claude" last="Hossein-Foucher">Claude Hossein-Foucher</name></author><author><name sortKey="Blum, David" sort="Blum, David" uniqKey="Blum D" first="David" last="Blum">David Blum</name></author><author><name sortKey="Sablonniere, Bernard" sort="Sablonniere, Bernard" uniqKey="Sablonniere B" first="Bernard" last="Sablonnière">Bernard Sablonnière</name></author><author><name sortKey="Schraen, Susanna" sort="Schraen, Susanna" uniqKey="Schraen S" first="Susanna" last="Schraen">Susanna Schraen</name></author><author><name sortKey="Allorge, Delphine" sort="Allorge, Delphine" uniqKey="Allorge D" first="Delphine" last="Allorge">Delphine Allorge</name></author><author><name sortKey="Destee, Alain" sort="Destee, Alain" uniqKey="Destee A" first="Alain" last="Destée">Alain Destée</name></author><author><name sortKey="Bordet, Regis" sort="Bordet, Regis" uniqKey="Bordet R" first="Régis" last="Bordet">Régis Bordet</name></author><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name></author></analytic><series><title level="j">Journal of neurology, neurosurgery, and psychiatry</title><idno type="eISSN">1468-330X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Dyskinesia, Drug-Induced (prevention & control)</term><term>Female</term><term>Gait Disorders, Neurologic (drug therapy)</term><term>Gait Disorders, Neurologic (etiology)</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Memantine (adverse effects)</term><term>Memantine (therapeutic use)</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Pilot Projects</term><term>Sample Size</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term><term>Memantine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term><term>Memantine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Gait Disorders, Neurologic</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Gait Disorders, Neurologic</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term><term>Sample Size</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Given that memantine is thought to decrease N-methyl-D-aspartic-acid-related (NMDA) glutamatergic hyperactivity and improve locomotion in rats, we sought to assess the drug's impact on axial symptoms in advanced Parkinson's disease (PD).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23077087</PMID><DateCreated><Year>2013</Year><Month>04</Month><Day>10</Day></DateCreated><DateCompleted><Year>2013</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J. Neurol. Neurosurg. Psychiatr.</ISOAbbreviation></Journal><ArticleTitle>Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.</ArticleTitle><Pagination><MedlinePgn>552-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2012-303182</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Given that memantine is thought to decrease N-methyl-D-aspartic-acid-related (NMDA) glutamatergic hyperactivity and improve locomotion in rats, we sought to assess the drug's impact on axial symptoms in advanced Parkinson's disease (PD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a 90-day, randomised, double-blind, study with two parallel arms: 20 mg/day memantine versus placebo (ClinicalTrials.gov:NCT01108029). The main inclusion criterion was the presence of a severe gait disorder and an abnormal, forward-leaning stance. The following parameters were analysed under standardised conditions before and after acute administration of L-dopa: gait (stride length as primary criterion), the United-Parkinson's-Disease-Rating-Scale (UPDRS) motor score and its axial subscore, the hypertonia and strength of the axial extensors and flexors (isokinetic dynamometer), the Dyskinesia Rating Scale score (DRS) and its axial subscore.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-five patients were included. The memantine and placebo group did not differ significantly in terms of stride length. However, in the memantine group, we observed significantly better results (vs placebo) for the overall UPDRS score (F(1,21)=4.9; p=0.039(-1)) and its axial subscore (F(1,21)=7.2; p=0.014(-1.1)), axial hypertonia, the axial and overall DRS and axial strength.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Memantine treatment was associated with lower axial motor symptom and dyskinesia scores but did not improve gait. These benefits must be confirmed in a broader population of patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreau</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Lille Nord de France and Lille University Hospital, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delval</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tiffreau</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Defebvre</LastName><ForeName>Luc</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Dujardin</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Duhamel</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Petyt</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hossein-Foucher</LastName><ForeName>Claude</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sablonnière</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Schraen</LastName><ForeName>Susanna</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Allorge</LastName><ForeName>Delphine</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Destée</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bordet</LastName><ForeName>Régis</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Devos</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01108029</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Brain. 2000 Sep;123 ( Pt 9):1767-83</RefSource><PMID Version="1">10960043</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 Jun 15;24(8):1176-82</RefSource><PMID Version="1">19412964</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol. 2001 Nov;248(11):950-8</RefSource><PMID Version="1">11757958</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Behav Brain Res. 2004 May 5;151(1-2):17-23</RefSource><PMID Version="1">15084417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arzneimittelforschung. 1977 Jul;27(7):1487-9</RefSource><PMID Version="1">332193</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Dtsch Med Wochenschr. 1984 Jun 22;109(25):987-90</RefSource><PMID Version="1">6734455</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52</RefSource><PMID Version="1">2841426</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Park Dis Dement Sect. 1992;4:277-82</RefSource><PMID Version="1">1388698</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm Gen Sect. 1994;98(1):57-67</RefSource><PMID Version="1">7710739</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychopharmacology (Berl). 1995 May;119(1):55-65</RefSource><PMID Version="1">7675950</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1998 Sep;44(3 Suppl 1):S175-88</RefSource><PMID Version="1">9749591</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 1999 Sep-Oct;22(5):273-6</RefSource><PMID Version="1">10516877</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Pharmacol. 2006 Feb;6(1):61-7</RefSource><PMID Version="1">16368266</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2007 May;78(5):470-5</RefSource><PMID Version="1">17098845</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bull Exp Biol Med. 2000 Jul;130(7):629-32</RefSource><PMID Version="1">11140570</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020233" MajorTopicYN="N">Gait Disorders, Neurologic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3623038</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23077087</ArticleId><ArticleId IdType="pii">jnnp-2012-303182</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2012-303182</ArticleId><ArticleId IdType="pmc">PMC3623038</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000706 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000706 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:23077087
|texte= Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:23077087" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |